Chen Shang-Wen, Liang Ji-An, Hung Yao-Ching, Yeh Lian-Shung, Chang Wei-Chun, Yang Shih-Neng, Lin Fang-Jen
Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan.
Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1335-43. doi: 10.1016/j.ijrobp.2008.12.018. Epub 2009 Apr 20.
This study aimed to assess the predictive values of geometrical sparing factors for the rectum and bladder in high-dose-rate intracavitary brachytherapy (HDRICB) for Grade 2 and higher late sequelae in patients with cervical cancer.
A total of 392 patients were enrolled in this study. They were treated with external beam radiotherapy to the pelvis, after which HDRICB was performed using Ir-192 remote after-loading at 1-week intervals for three or four sessions. The geometrical sparing factor (GSF) was defined as the average of the ratios between the reference doses and the Point A dose.
A total of 46 patients (11.7%) had Grade 2 or higher late rectal complications (36 Grade 2, 9 Grade 3, and 1 Grade 4). In all, 32 patients (8.2%) had Grade 2 or higher late bladder complications (14 Grade 2, 16 Grade 3, and 2 Grade 4). Multivariate analysis demonstrated a high risk of rectal sequelae in patients who developed bladder complications (p = 0.0004, hazard ratio 3.54) and had a rectal GSF greater than 0.7 (p = 0.01, hazard ratio 1.99). The high risk factors for bladder complications were development of rectal complications (p = 0.0004, hazard ratio 3.74), concurrent chemotherapy (p = 0.0001, relative risk 3.94), and a bladder GSF greater than 0.9 (p = 0.01, hazard ratio, 2.53).
This study demonstrates the predictive value of GSFs in HDRICB for cervical cancer. Patients with rectal GSFs greater than 0.7 or bladder GSFs greater than 0.9 are at risk for Grade 2 and higher late sequelae.
本研究旨在评估高剂量率腔内近距离放射治疗(HDRICB)中直肠和膀胱的几何保留因子对宫颈癌患者2级及以上晚期后遗症的预测价值。
本研究共纳入392例患者。他们接受了盆腔外照射放疗,之后使用铱-192遥控后装进行HDRICB,每隔1周进行一次,共三或四次。几何保留因子(GSF)定义为参考剂量与A点剂量之比的平均值。
共有46例患者(11.7%)发生2级或以上晚期直肠并发症(36例2级,9例3级,1例4级)。共有32例患者(8.2%)发生2级或以上晚期膀胱并发症(14例2级,16例3级,2例4级)。多因素分析显示,发生膀胱并发症的患者(p = 0.0004,风险比3.54)以及直肠GSF大于0.7的患者(p = 0.01,风险比1.99)发生直肠后遗症的风险较高。膀胱并发症的高危因素包括发生直肠并发症(p = 0.0004,风险比3.74)、同步化疗(p = 0.0001,相对风险3.94)以及膀胱GSF大于0.9(p = 0.01,风险比2.53)。
本研究证明了GSF在宫颈癌HDRICB中的预测价值。直肠GSF大于0.7或膀胱GSF大于0.9的患者有发生2级及以上晚期后遗症的风险。